보고서 요약(국문)

개요
글로벌 신약 개발 아웃소싱 서비스 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
신약 개발 아웃소싱 서비스는 다양한 치료 분야 또는 질병에 대한 신약의 발견 및 개발을 촉진하기 위한 과학 및 기술 서비스 범위를 의미합니다. 신약 개발 과정에는 질병 과정에 관여하는 단백질이나 유전자와 같은 잠재적 약물 표적을 식별하고 치료 잠재력을 검증하는 표적 식별, 의약 화학, 약물의 체내 작용 및 잠재적 부작용을 평가하는 흡수, 분포, 대사, 배설 및 독성(ADME-TOX) 연구, 효능, 안전성 및 약리학적 특성을 평가하는 약리학 연구, 그리고 임상 시험에 이어지는 전임상 개발 및 제형 개발이 포함됩니다.

시장 동향: 동인 및 제약 요인
AI 기반 신약 개발 방법의 증가
AI를 활용하려는 기업은 단편적인 데이터가 아닌 모든 데이터를 전체적으로 파악해야 합니다. 이를 위해서는 계산 및 실험 팀이 협업하고 워크플로우를 통합하며 도메인과 위치에 관계없이 데이터를 공유할 수 있는 연구 인프라가 필요합니다. AI를 통해 얻은 결과의 재현성을 보장하기 위해서는 신중한 프로세스 및 방법론 표준화 또한 필수적입니다.
예를 들어, 2023년 7월, 킷세이 제약(Kissei Pharmaceutical Co., Ltd.)은 이크토스(Iktos)의 AI 기반 신약 개발 시스템인 마키아(Makya)를 출시했습니다. 이 시스템은 AI 기술을 활용하여 표적 기준에 적합한 새로운 소분자 화합물을 신속하게 설계할 수 있도록 지원함으로써 신약 개발 속도를 향상시킵니다.
또한, 2023년 5월, 구글 클라우드(Google Cloud)는 생명공학 기업, 제약 회사 및 공공 부문 기관의 신약 개발 및 정밀 의학을 가속화하기 위한 두 가지 새로운 AI 기반 생명 과학 솔루션을 발표했습니다. 전 세계에서 사용 가능한 표적 및 선도 물질 식별 제품군(Target and Lead Identification Suite)은 연구자들이 아미노산의 기능을 더 잘 파악하고 단백질 구조를 예측하는 데 도움을 줍니다. 멀티오믹스 스위트는 유전체 데이터의 발견 및 해석을 가속화하여 기업이 정밀 치료법을 설계할 수 있도록 지원합니다.
또한 만성 질환의 증가, 생물학적 제제 시장의 확장, 연구 개발 시설의 증가와 같은 요인들이 제약 약물 전달 시장을 성장시키고 있으며, AI 통합 및 의료 디지털화와 같은 최신 기술 발전은 시장에 새로운 기회를 창출하고 있습니다.
시장 동향: 제약 요인
전 세계 신약 개발 아웃소싱 시장의 성장을 저해할 것으로 예상되는 주요 요인 중 하나는 신약 개발 비용의 상승입니다. 신약 개발은 비용이 많이 들고 시간이 오래 걸리는 장기적인 과정입니다. 신약 개발을 위한 전임상 연구와 관련된 높은 비용이 가장 큰 어려움입니다. 또한 의약품 제조에 대한 엄격한 규정, 지적 재산권, CMO의 규제 요건 미준수 위험 등도 예측 기간 동안 시장 성장을 저해하는 요인으로 작용합니다.
세분화 분석
전 세계 신약 개발 아웃소싱 서비스 시장은 서비스 유형, 의약품 유형, 치료 영역, 최종 사용자 및 지역별로 세분화됩니다.

서비스 유형 부문 중 생물학 서비스 부문은 신약 개발 아웃소싱 서비스 시장 점유율의 약 41.7%를 차지했습니다.
생물학 서비스 부문은 약 41.7%를 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 생물학 서비스는 세포, 조직, 생체 분자와 같은 생물학적 시스템을 연구하고 조작하여 잠재적인 치료 화합물을 식별하고 개발하는 데 도움이 되는 다양한 전문 서비스를 포함합니다. 생물학 서비스는 복잡한 잠재적 신약 후보 물질과 생체 내 유기체 간의 상호 작용을 세포 및 분자 수준에서 평가하는 데 중요한 역할을 합니다.
예를 들어, BenchSci는 2023년 1월 신약 개발의 중요한 단계에서 결과와 일정을 혁신하고 개선하는 것을 목표로 하는 최신 기술 출시를 발표하게 되어 기쁩니다. BenchSci의 혁신적인 새로운 AI 소프트웨어 플랫폼인 ASCEND는 전임상 연구를 근본적으로 바꿀 잠재력을 가지고 있습니다. AI 기반 시약 선택 애플리케이션의 성공을 바탕으로, 과학자들이 생물학적 연관성을 발견하고, 시행착오 실험을 획기적으로 줄이며, 위험 요소를 조기에 파악하여 가장 유망한 프로젝트를 더 빠르게 진행할 수 있도록 지원하는 새로운 애플리케이션을 개발했습니다.
지역 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 기술 발전, 잘 구축된 연구 인프라 및 주요 기업의 존재, 신약 개발 연구 개발에 대한 높은 투자, 주요 기업 인수, 효율성, 품질 및 혁신에 대한 요구 증가 등으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
예를 들어, 2022년 4월 Charles River Laboratories International과 Valo Health는 고객의 생물학적 통찰력을 최적화된 전임상 자산으로 전환하는 AI 기반 신약 솔루션인 Logica를 출시했습니다. 이 솔루션은 Valo의 AI 기반 Opal 컴퓨팅 플랫폼과 Charles River의 전임상 전문성을 활용하여 고객에게 표적을 후보 물질로 전환하는 단일 통합 서비스를 제공합니다. 이 파트너십은 Charles River의 연구실 역량과 AI 기반 분자 설계를 통합하여 고객에게 고급 리드 및 후보 물질을 제공하는 동시에 고객 비용을 가치 창출과 연계하는 것을 목표로 합니다.
또한, Labcorp는 2021년 12월 비임상 시험 서비스를 제공하는 위탁 연구 회사인 Toxikon Corporation을 인수했다고 발표했습니다. Toxikon의 합류로 LabCorp의 신약 개발 포트폴리오가 강화되었으며, 제약 및 생명공학 고객과의 파트너십을 위한 전략적 기반을 구축하는 데 도움이 될 것입니다.
COVID-19 영향 분석
COVID-19는 지난 3년간 다양한 제약 및 생명공학 기업의 백신 개발 수요 급증으로 인해 신약 개발 아웃소싱 서비스 시장에 상당한 영향을 미쳤습니다. 신약 개발 아웃소싱은 바이러스에 대한 효과적인 치료법 개발의 핵심 요소가 되었습니다. 예를 들어, 2021년 6월, Catalent, Inc.는 Moderna, Inc.와 협력하여 인디애나주 블루밍턴에 있는 Catalent의 생물학 제제 시설에서 Moderna COVID-19 백신 및 Moderna의 파이프라인에 있는 다른 임상 연구 프로그램들을 생산하기로 했습니다.
시장 세분화
서비스 유형별
• 의료화학 서비스
• 생물학 서비스
약물 유형별
• 소분자
• 대분자(바이오의약품)
치료 분야별
• 종양학
• 감염성 질환
• 호흡기 질환
• 심혈관 질환
• 위장관 질환
• 기타
최종 사용자별
• 임상시험수탁기관(CRO)
• 제약 및 생명공학 기업
• 학술기관
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 ThermoFisher Scientific, Charles River Laboratories International Inc., WuXi 등이 있습니다. AppTec Co.Ltd., Albany Molecular Research, Inc., Aragen Life Sciences Ltd, Sygnature Discovery, Pharmaron Beijing Co. Ltd, Domainex Ltd., Jubilant Biosys Ltd., Evotec 등이 있습니다.
주요 개발 사항
 2022년 11월, 임상 단계 바이오 기술 기업인 Insilico Medicine과 Sanofi는 12억 달러 규모의 신약 개발 계약을 체결했습니다. 이 계약을 통해 Sanofi는 Insilico의 AI 플랫폼인 Pharma.AI를 활용하여 최대 6개의 새로운 표적에 대한 신약 개발을 진행할 예정입니다.

 2022년 10월, 표적 단백질 분해(TPD)를 이용한 신약 개발 프로젝트에 주력하는 바이오 기술 기업인 Amphista Therapeutics는 의약품 연구 서비스 파트너인 Domainex와 협력하여 연구 프로그램에 필요한 통합 신약 개발 서비스를 제공받기로 했습니다. Amphista는 Domainex의 단백질 생산, 분석 생물학 및 의약 화학 분야의 전문성을 활용할 수 있게 됩니다.
보고서 구매 이유

• 서비스 유형, 의약품 유형, 치료 분야, 최종 사용자 및 지역별 글로벌 신약 개발 아웃소싱 서비스 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 신약 개발 아웃소싱 서비스 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 신약 개발 아웃소싱 서비스 시장 보고서는 약 61개의 표, 58개의 그림, 187페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Drug Discovery Outsourcing Services Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
Drug discovery outsourcing services refer to the range of scientific and technological services to facilitate the discovery and development of new drugs for various therapeutic areas or diseases. The drug discovery process includes target identification to identify potential drug targets, such as proteins or genes involved in disease processes, and validate their therapeutic potential. medicinal chemistry, ADME-TOX studies which are absorption, distribution, metabolism, excretion, and toxicity to assess the behaviour of the drug within the body and its potential adverse effects, pharmacology studies to assess the efficacy, safety and pharmacological properties and preclinical development and formulation development followed by clinical trials.
Market Dynamics: Drivers and Restraints
Rise in the AI-enabled drug discovery methods
Companies hoping to leverage AI need a full view of all their data, not just bits and pieces. This demands a research infrastructure that lets computational and experimental teams collaborate, uniting workflows and sharing data across domains and locations. Careful process and methodology standardization are also needed to ensure that results obtained with the help of AI are repeatable.
For instance, in July 2023, kissei Pharmaceutical Co., Ltd. introduced Makya, an AI drug discovery system from Iktos. This will enable the rapid design of new small molecules suitable for target criteria using AI technology, leading to an increase in the speed of drug discovery and development.
Moreover, in May 2023, Google Cloud announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. Available worldwide, the Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and interpretation of genomic data, helping companies design precision treatments.
Furthermore, factors like the rise in chronic diseases, expanding biologics market, and increasing research and development facilities are increasing the pharmaceutical drug delivery market, latest technological advancements such as Al integration and healthcare digitization create new opportunities for the market.
Market Dynamics: Restraint
One of the key factors expected to hamper the growth of the global drug discovery outsourcing market is the high cost of drug development. Drug development is an expensive, time-consuming, and long-term process. Higher costs associated with preclinical studies for drug discovery are the biggest challenge. Also, other factors like stringent rules & regulations for drug manufacturing, intellectual property rights, Risk of non-compliance with regulatory requirements by CMO and others factors hamper the market growth during the forecast period.
Segment Analysis
The global drug discovery outsourcing services market is segmented based on service type, drug type, therapeutic areas, end user and region.
The biology services segment from the service type segment accounted for approximately 41.7% of the drug discovery outsourcing services market share
The biology services segment from the service type segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Biological services encompass a range of specialized offerings that involve the study and manipulation of biological systems, such as cells, tissues, and biomolecules, to facilitate the identification and development of potential therapeutic compounds. Biological services play a pivotal role in assessing the interactions between complex potential drug candidates and living organisms at the cellular and molecular levels.
For instance, in January 2023, BenchSci is excited to announce the launch of our latest technology that aims to transform and improve outcomes and timelines for this crucial stage of drug discovery. ASCEND by BenchSci, our revolutionary new AI software platform has the potential to fundamentally change preclinical research. Building on the success of our AI-assisted reagent selection application, we’ve developed new applications to empower scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early to move the most promising projects forward faster.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the technological advancements, presence of well-established research infrastructure & key players, and higher investments in drug discovery R&D, acquisitions with key players, rising need for efficiency, quality, and innovation are expected to contribute to market growth.
For instance, in April 2022, Charles River Laboratories International and Valo Health launched Logica, an AI-powered drug solution that translates clients' biological insights into optimized preclinical assets. The solution uses Valo's AI-powered Opal Computational Platform and Charles River's preclinical expertise to provide clients with a single integrated offering, translating targets to candidate nominations. The partnership aims to integrate Charles River's laboratory capabilities with AI-driven molecular design, providing clients with advanced leads and candidates while tying client costs to value generation.
Moreover, in December 2021, Labcorp stated that it had acquired Toxikon Corporation, a contract research company offering nonclinical testing services. The addition of Toxikon to LabCorp drug development enhances the company's strong nonclinical development portfolio and assists in generating a strategic footprint for the company to partner with pharmaceutical and biotechnology clients.
COVID-19 Impact Analysis
COVID-19 had a substantial impact on the drug discovery outsourcing services market owing to the high demand for vaccine discovery by various pharmaceutical and biotech companies in the past three years. Drug discovery outsourcing has become a key aspect of developing effective treatments against the virus. For instance, in June 2021, Catalent, Inc. collaborated with Moderna, Inc. for the manufacturing of the Moderna COVID-19 vaccine and potentially other investigational programs in Moderna’s pipeline at Catalent’s biologics facility in Bloomington, Indiana.
Market Segmentation
By Service Type
• Medical Chemistry Services
• Biology Services
By Drug Type
• Small Molecule
• Large Molecules (Biopharmaceuticals)
By Therapeutic Areas
• Oncology
• Infectious Disease
• Respiratory Disease
• Cardiovascular
• Gastrointestinal
• Others
By End User
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Academic Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include ThermoFisher Scientific, Charles River Laboratories International Inc., WuXi AppTec Co.Ltd., Albany Molecular Research, Inc., Aragen Life Sciences Ltd, Sygnature Discovery, Pharmaron Beijing Co. Ltd, Domainex Ltd., Jubilant Biosys Ltd., Evotec and among others.
Key Developments
 In November 2022, Sanofi and Insilico Medicine, a clinical-stage biotechnology company, inked a USD 1200 million Drug Development Deal. The agreement will see Sanofi use Insilico’s AI platform, Pharma.AI, to advance drug development in up to six new targets.
 In October 2022, Amphista Therapeutics, a biotechnology company focusing on drug discovery projects that use targeted protein degradation (TPD), collaborated with Domainex, a medicines research service partner, as a partner to provide integrated drug discovery services for its research programs. Amphista will benefit from the expertise in protein production, assay biology, and medicinal chemistry of Domainex.
Why Purchase the Report?
• To visualize the global drug discovery outsourcing services market segmentation based on service type, drug type, therapeutic areas, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of drug discovery outsourcing services market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global drug discovery outsourcing services market report would provide approximately 61 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Service Type
3.2. Snippet by Drug Type
3.3. Snippet by Therapeutic Areas
3.4. Snippet by End User
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the AI-enabled drug discovery methods
4.1.1.2. Rise in the prevalence of chronic diseases
4.1.2. Restraints
4.1.2.1. High cost of drug discovery
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Service Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
7.1.2. Market Attractiveness Index, By Service Type
7.2. Medical Chemistry Services*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Biology Services
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Small Molecule *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Large Molecules (Biopharmaceuticals)
9. By Therapeutic Areas
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
9.1.2. Market Attractiveness Index, By Therapeutic Areas
9.2. Oncology *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Infectious Disease
9.4. Respiratory Disease
9.5. Cardiovascular
9.6. Gastrointestinal
9.7. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Contract Research Organizations*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pharmaceutical & Biotechnology Companies
10.4. Academic Institutes
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. ThermoFisher Scientific*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Charles River Laboratories International, Inc
13.3. WuXi AppTec Co., Ltd.,
13.4. Albany Molecular Research, Inc.,
13.5. Aragen Life Sciences Ltd
13.6. Sygnature Discovery,
13.7. Pharmaron Beijing Co., Ltd.,
13.8. Domainex Ltd.,
13.9. Jubilant Biosys Ltd.
13.10. Evotec
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

ThermoFisher Scientific, 4.	Key Developments, Charles River Laboratories International, Inc, WuXi AppTec Co., Ltd.,, Albany Molecular Research, Inc.,, Aragen Life Sciences Ltd, Sygnature Discovery,, Pharmaron Beijing Co., Ltd.,, Domainex Ltd.,, Jubilant Biosys Ltd., Evotec

표 목록 (Tables)

List of Tables Table 1 Global Drug Discovery Outsourcing Services Market Value, By Service Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Drug Discovery Outsourcing Services Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Drug Discovery Outsourcing Services Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Drug Discovery Outsourcing Services Market Value, By Service Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Drug Discovery Outsourcing Services Market Value, By Service Type, 2021-2030 (US$ Million)

Table 7 Global Drug Discovery Outsourcing Services Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Drug Discovery Outsourcing Services Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 9 Global Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2021-2030 (US$ Million)

Table 11 Global Drug Discovery Outsourcing Services Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Drug Discovery Outsourcing Services Market Value, By End User, 2021-2030 (US$ Million)

Table 13 North America Drug Discovery Outsourcing Services Market Value, By Service Type, 2021-2030 (US$ Million)

Table 14 North America Drug Discovery Outsourcing Services Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 15 North America Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2021-2030 (US$ Million)

Table 16 North America Drug Discovery Outsourcing Services Market Value, By End User, 2021-2030 (US$ Million)

Table 17 North America Drug Discovery Outsourcing Services Market Value, By Country, 2021-2030 (US$ Million)

Table 18 South America Drug Discovery Outsourcing Services Market Value, By Service Type, 2021-2030 (US$ Million)

Table 19 South America Drug Discovery Outsourcing Services Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 20 South America Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2021-2030 (US$ Million)

Table 21 South America Drug Discovery Outsourcing Services Market Value, By End User, 2021-2030 (US$ Million)

Table 22 South America Drug Discovery Outsourcing Services Market Value, By Country, 2021-2030 (US$ Million)

Table 23 Europe Drug Discovery Outsourcing Services Market Value, By Service Type, 2021-2030 (US$ Million)

Table 24 Europe Drug Discovery Outsourcing Services Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 25 Europe Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2021-2030 (US$ Million)

Table 26 Europe Drug Discovery Outsourcing Services Market Value, By End User, 2021-2030 (US$ Million)

Table 27 Europe Drug Discovery Outsourcing Services Market Value, By Country, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Drug Discovery Outsourcing Services Market Value, By Service Type, 2021-2030 (US$ Million)

Table 29 Asia-Pacific Drug Discovery Outsourcing Services Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 30 Asia-Pacific Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Drug Discovery Outsourcing Services Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Drug Discovery Outsourcing Services Market Value, By Country, 2021-2030 (US$ Million)

Table 33 Middle East & Africa Drug Discovery Outsourcing Services Market Value, By Service Type, 2021-2030 (US$ Million)

Table 34 Middle East & Africa Drug Discovery Outsourcing Services Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 35 Middle East & Africa Drug Discovery Outsourcing Services Market Value, By Therapeutic Areas, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Drug Discovery Outsourcing Services Market Value, By End User, 2021-2030 (US$ Million)

Table 37 ThermoFisher Scientific: Overview

Table 38 ThermoFisher Scientific: Product Portfolio

Table 39 ThermoFisher Scientific: Key Developments

Table 40 Charles River Laboratories International, Inc: Overview

Table 41 Charles River Laboratories International, Inc: Product Portfolio

Table 42 Charles River Laboratories International, Inc: Key Developments

Table 43 WuXi AppTec Co., Ltd.: Overview

Table 44 WuXi AppTec Co., Ltd.: Product Portfolio

Table 45 WuXi AppTec Co., Ltd.: Key Developments

Table 46 Albany Molecular Research, Inc.: Overview

Table 47 Albany Molecular Research, Inc.: Product Portfolio

Table 48 Albany Molecular Research, Inc.: Key Developments

Table 49 Aragen Life Sciences Ltd: Overview

Table 50 Aragen Life Sciences Ltd: Product Portfolio

Table 51 Aragen Life Sciences Ltd: Key Developments

Table 52 Sygnature Discovery: Overview

Table 53 Sygnature Discovery: Product Portfolio

Table 54 Sygnature Discovery: Key Developments

Table 55 Pharmaron Beijing Co., Ltd.: Overview

Table 56 Pharmaron Beijing Co., Ltd.: Product Portfolio

Table 57 Pharmaron Beijing Co., Ltd.: Key Developments

Table 58 Domainex Ltd.: Overview

Table 59 Domainex Ltd.: Product Portfolio

Table 60 Domainex Ltd., Key Developments

Table 61 Jubilant Biosys Ltd.: Overview

Table 62 Jubilant Biosys Ltd.: Product Portfolio

Table 63 Jubilant Biosys Ltd.: Key Developments

Table 64 Evotec: Overview

Table 65 Evotec: Product Portfolio

그림 목록 (Figures)

List of Figures Figure 1 Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 2 Global Drug Discovery Outsourcing Services Market Share, By Service Type, 2022 & 2030 (%)

Figure 3 Global Drug Discovery Outsourcing Services Market Share, By Drug Type, 2022 & 2030 (%)

Figure 4 Global Drug Discovery Outsourcing Services Market Share, By Therapeutic Areas, 2022 & 2030 (%)

Figure 5 Global Drug Discovery Outsourcing Services Market Share, By End User, 2022 & 2030 (%)

Figure 6 Global Drug Discovery Outsourcing Services Market Y-o-Y Growth, By Service Type, 2022-2030 (%)

Figure 7 Medical Chemistry Services Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 8 Biology Services Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 9 Global Drug Discovery Outsourcing Services Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 10 Small Molecule Drug Type in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 11 Large Molecules (Biopharmaceuticals) Drug Type in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 12 Global Drug Discovery Outsourcing Services Market Y-o-Y Growth, By Therapeutic Areas, 2022-2030 (%)

Figure 13 Oncology Therapeutic Areas in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 14 Infectious Disease Therapeutic Areas in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 15 Respiratory Disease Therapeutic Areas in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 16 Cardiovascular Therapeutic Areas in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 17 Gastrointestinal Therapeutic Areas in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 18 Others Therapeutic Areas in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 19 Global Drug Discovery Outsourcing Services Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 20 Contract Research Organizations End User in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 21 Pharmaceutical & Biotechnology Companies End User in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 22 Academic Institutes End User in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 23 Others End User in Global Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 24 Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 25 Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 26 Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 27 Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 28 North America Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 29 North America Drug Discovery Outsourcing Services Market Share, By Service Type, 2022 & 2030 (%)

Figure 30 North America Drug Discovery Outsourcing Services Market Share, By Drug Type, 2022 & 2030 (%)

Figure 31 North America Drug Discovery Outsourcing Services Market Share, By Therapeutic Areas, 2022 & 2030 (%)

Figure 32 North America Drug Discovery Outsourcing Services Market Share, By End User, 2022 & 2030 (%)

Figure 33 North America Drug Discovery Outsourcing Services Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 35 South America Drug Discovery Outsourcing Services Market Share, By Service Type, 2022 & 2030 (%)

Figure 36 South America Drug Discovery Outsourcing Services Market Share, By Drug Type, 2022 & 2030 (%)

Figure 37 South America Drug Discovery Outsourcing Services Market Share, By Therapeutic Areas, 2022 & 2030 (%)

Figure 38 South America Drug Discovery Outsourcing Services Market Share, By End User, 2022 & 2030 (%)

Figure 39 South America Drug Discovery Outsourcing Services Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Drug Discovery Outsourcing Services Market Share, By Service Type, 2022 & 2030 (%)

Figure 42 Europe Drug Discovery Outsourcing Services Market Share, By Drug Type, 2022 & 2030 (%)

Figure 43 Europe Drug Discovery Outsourcing Services Market Share, By Therapeutic Areas, 2022 & 2030 (%)

Figure 44 Europe Drug Discovery Outsourcing Services Market Share, By End User, 2022 & 2030 (%)

Figure 45 Europe Drug Discovery Outsourcing Services Market Share, By Country, 2022 & 2030 (%)

Figure 46 Asia-Pacific Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 47 Asia-Pacific Drug Discovery Outsourcing Services Market Share, By Service Type, 2022 & 2030 (%)

Figure 48 Asia-Pacific Drug Discovery Outsourcing Services Market Share, By Drug Type, 2022 & 2030 (%)

Figure 49 Asia-Pacific Drug Discovery Outsourcing Services Market Share, By Therapeutic Areas, 2022 & 2030 (%)

Figure 50 Asia-Pacific Drug Discovery Outsourcing Services Market Share, By End User, 2022 & 2030 (%)

Figure 51 Asia-Pacific Drug Discovery Outsourcing Services Market Share, By Country, 2022 & 2030 (%)

Figure 52 Middle East & Africa Drug Discovery Outsourcing Services Market Value, 2021-2030 (US$ Million)

Figure 53 Middle East & Africa Drug Discovery Outsourcing Services Market Share, By Service Type, 2022 & 2030 (%)

Figure 54 Middle East & Africa Drug Discovery Outsourcing Services Market Share, By Drug Type, 2022 & 2030 (%)

Figure 55 Middle East & Africa Drug Discovery Outsourcing Services Market Share, By Therapeutic Areas, 2022 & 2030 (%)

Figure 56 Middle East & Africa Drug Discovery Outsourcing Services Market Share, By End User, 2022 & 2030 (%)

Figure 57 ThermoFisher Scientific: Financials

Figure 58 Charles River Laboratories International, Inc: Financials

Figure 59 WuXi AppTec Co., Ltd., Financials

Figure 60 Albany Molecular Research, Inc., Financials

Figure 61 Aragen Life Sciences Ltd: Financials

Figure 62 Sygnature Discovery, Financials

Figure 63 Pharmaron Beijing Co., Ltd.: Financials

Figure 64 Domainex Ltd., Financials

Figure 65 Jubilant Biosys Ltd.: Financials

Figure 66 Evotec: Financials

글로벌 신약 개발 아웃소싱 서비스 시장 – 2023-2030

Global Drug Discovery Outsourcing Services Market - 2023-2030